Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis

Arthritis and Rheumatism

Volumn 65, Issue 9, 2013, Pages 2469-2475

  Vaglio, Augusto ^a   Catanoso, Maria G ^b   Spaggiari, Lucia ^b   Magnani, Luca ^b   Pipitone, Nicolò ^b   MacChioni, Pierluigi ^b   Pulsatelli, Lia ^c   Nicastro, Maria ^a   Becchi, Gabriella ^d   Corradi, Domenico ^d   Versari, Annibale ^b   Boiardi, Luigi ^b   Salvarani, Carlo ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACUTE PHASE PROTEIN; AZATHIOPRINE; C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; METHOTREXATE; PREDNISONE; TAMOXIFEN; TOCILIZUMAB;

ABDOMINAL AORTA; ABDOMINAL PAIN; ADD ON THERAPY; ADULT; AGED; ANXIETY; AORTITIS; ARTICLE; B LYMPHOCYTE; CHRONIC PERIAORTITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; CONSTIPATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FIBROBLAST; HALLUCINATION; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; IRRITABILITY; LOW BACK PAIN; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RELAPSE; REMISSION; SIDE EFFECT; SMOOTH MUSCLE FIBER; SUICIDAL IDEATION; T LYMPHOCYTE; THORACIC AORTA; VASCULAR SMOOTH MUSCLE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-6; RETROPERITONEAL FIBROSIS; TREATMENT OUTCOME;

EID: 84883260218     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38032     Document Type: Article

References (15)

1. Palmisano A, Vaglio A,. Chronic periaortitis: a fibro-inflammatory disorder. Best Pract Res Clin Rheumatol 2009; 23: 339-53.
2. Parums DV,. The spectrum of chronic periaortitis. Histopathology 1990; 16: 423-31.
3. Vaglio A, Palmisano A, Alberici F, Maggiore U, Ferretti S, Cobelli R, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. Lancet 2011; 378: 338-46.
4. Binder M, Uhl M, Wiech T, Kollert F, Thiel J, Sass JO, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012; 71: 311-2.
5. Scheel PJ Jr, Feeley N, Sozio SM,. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 2011; 154: 31-6.
6. Kaly L, Rosner I,. Tocilizumab-a novel therapy for non-organ-specific autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26: 157-65.
7. Catanoso MG, Spaggiari L, Magnani L, Pipitone N, Versari A, Boiardi L, et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 2012; 30: 776-8.
8. Scheel PJ Jr, Feeley N,. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine (Baltimore) 2009; 88: 202-7.
9. Salvarani C, Pipitone N, Versari A, Vaglio A, Serafini D, Bajocchi G, et al. Positron emission tomography (PET): evaluation of chronic periaortitis. Arthritis Rheum 2005; 53: 298-303.
10. Pipitone N, Ghinoi A, Versari A, Vaglio A, Palmisano A, Salvarani C,. Images in cardiovascular medicine: chronic periaortitis. Circulation 2008; 118: 1214-6.
11. Maritati F, Corradi D, Versari A, Casali M, Urban ML, Buzio C, et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis 2012; 71: 1262-4.
12. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011; 70: 1874-5.
13. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
14. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T,. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64.
15. O'Reilly S, Ciechomska M, Cant R, Hugle T, van Laar JM,. Interleukin-6, its role in fibrosing conditions. Cytokine Growth Factor Rev 2012; 23: 99-107.